Estimation nationale de l'incidence et de la mortalité par cancer en France entre 1980 et 2012. Partie 1 -Tumeurs solides. Saint-Maurice (Fra): Institut de veille sanitaire ,
Breast cancer incidence and time trend in France from 1990 to 2007: a population-based study from two French cancer registries, Annals of Oncology, vol.22, issue.2, pp.329-363, 2011. ,
DOI : 10.1093/annonc/mdq396
Understanding recent trends in incidence of invasive breast cancer in Norway: age-period-cohort analysis based on registry data on mammography screening and hormone treatment use, BMJ, vol.344, issue.jan30 1, p.299, 2012. ,
DOI : 10.1136/bmj.e299
Dépistage organisé du cancer du sein -Évaluation épidémiologique -Données 2005. Saint-Maurice (Fra): Institut de veille sanitaire, p.366, 2008. ,
International comparison of performance measures for screening mammography: can it be done?, Journal of Medical Screening, vol.11, issue.4, pp.187-93, 2004. ,
DOI : 10.1258/0969141042467430
Prevalence of BRCA1 and BRCA2 Mutations in Male Breast Cancer Patients in Canada, Clinical Breast Cancer, vol.1, issue.1, pp.57-63, 2000. ,
DOI : 10.3816/CBC.2000.n.005
Epidemiology and Prevention of Breast Cancer, Annual Review of Public Health, vol.17, issue.1, pp.47-67, 1996. ,
DOI : 10.1146/annurev.pu.17.050196.000403
Facteurs de risque du cancer du sein, m??decine/sciences, vol.21, issue.2, pp.175-80, 2005. ,
DOI : 10.1051/medsci/2005212175
Breast cancer and hormone-replacement therapy: the Million Women Study, The Lancet, vol.362, issue.9392, pp.419-446, 2003. ,
DOI : 10.1016/S0140-6736(03)14596-5
The independent associations of parity, age at first full term pregnancy, and duration of breastfeeding with the risk of breast cancer, Journal of Clinical Epidemiology, vol.42, issue.10, pp.963-73, 1989. ,
DOI : 10.1016/0895-4356(89)90161-3
Grand multiparity and the risk of breast cancer: population-based study in Finland, Cancer Causes and Control, vol.12, issue.6, pp.491-500, 2001. ,
DOI : 10.1023/A:1011253527605
Chapter 1: Developmental, Cellular, and Molecular Basis of Human Breast Cancer, JNCI Monographs, vol.2000, issue.27, pp.17-37, 2000. ,
DOI : 10.1093/oxfordjournals.jncimonographs.a024241
Prophylactic mastectomy for the prevention of breast cancer, Cochrane Database Syst Rev, issue.11, p.2748, 2010. ,
Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families, The American Journal of Human Genetics, vol.62, issue.3, pp.676-89, 1998. ,
DOI : 10.1086/301749
Epidemiology of breast cancer, The Lancet Oncology, vol.2, issue.3, pp.133-173, 2001. ,
DOI : 10.1016/S1470-2045(00)00254-0
Lower Body Obesity*, The Journal of Clinical Endocrinology & Metabolism, vol.70, issue.2, pp.473-482, 1990. ,
DOI : 10.1210/jcem-70-2-473
Institut National du Cancer La prise en charge du cancer du sein, 2010. ,
Breast Cancer Risk Prediction and Mammography Biopsy Decisions, American Journal of Preventive Medicine, vol.44, issue.1, pp.15-22, 2013. ,
DOI : 10.1016/j.amepre.2012.10.002
The Biology of Cancer, Garland Science, vol.876, 2007. ,
Cancer du sein: questions et réponses au quotidien, 2009. ,
Preoperative Chemotherapy in Patients With Operable Breast Cancer: Nine-Year Results From National Surgical Adjuvant Breast and Bowel Project B-18, JNCI Monographs, vol.2001, issue.30, pp.96-102, 2001. ,
DOI : 10.1093/oxfordjournals.jncimonographs.a003469
The role of surgery in metastatic breast cancer, European Journal of Cancer, vol.47, pp.6-22, 1990. ,
DOI : 10.1016/S0959-8049(11)70142-3
Accréditation et d'Evaluation en Santé. La technique du ganglion sentinelle dans le cancer du sein ,
Importance of the level of axillary involvement in relation to traditional variables in the prognosis of breast cancer., International Journal of Oncology, vol.15, issue.3, pp.475-80, 1999. ,
DOI : 10.3892/ijo.15.3.475
Adjuvant radiotherapy for breast cancer significantly improves overall survival: the missing link, Radiotherapy and Oncology, vol.55, issue.3, pp.263-72, 2000. ,
DOI : 10.1016/S0167-8140(00)00204-8
Estrogen receptor and breast cancer, Seminars in Cancer Biology, vol.11, issue.5, pp.339-52, 2001. ,
DOI : 10.1006/scbi.2001.0389
Improvement in breast cancer survival between 1975 and 2003 in a cohort of 5722 women, Bull Cancer (Paris). avr, vol.93, issue.4, pp.391-400, 2006. ,
Tamoxifen in the Treatment of Breast Cancer, New England Journal of Medicine, vol.339, issue.22, pp.1609-1627, 1998. ,
DOI : 10.1056/NEJM199811263392207
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial, Annals of Oncology, vol.18, issue.5, pp.859-67, 2007. ,
DOI : 10.1093/annonc/mdm001
Survival With Aromatase Inhibitors and Inactivators Versus Standard Hormonal Therapy in Advanced Breast Cancer: Meta-analysis, JNCI: Journal of the National Cancer Institute, vol.98, issue.18 ,
DOI : 10.1093/jnci/djj357
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer, Journal of Clinical Oncology, vol.20, issue.3, pp.719-745, 2002. ,
DOI : 10.1200/JCO.20.3.719
Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840, Journal of Clinical Oncology, vol.26, issue.10, pp.1642-1651, 2008. ,
DOI : 10.1200/JCO.2007.11.6699
Untangling the ErbB signalling network, Nature Reviews Molecular Cell Biology, vol.2, issue.2, pp.127-164, 2001. ,
DOI : 10.1038/35052073
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer, New England Journal of Medicine, vol.353, issue.16, pp.1673-84, 2005. ,
DOI : 10.1056/NEJMoa052122
Breast cancer metastasis, Cancer Genomics Proteomics. oct, vol.9, issue.5, pp.311-331, 2012. ,
Breast cancer metastasis: markers and models, Nature Reviews Cancer, vol.945, issue.8, pp.591-602, 2005. ,
DOI : 10.1038/nm0803-999b
Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer., Journal of Clinical Oncology, vol.14, issue.8, pp.2197-205, 1996. ,
DOI : 10.1200/JCO.1996.14.8.2197
Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer, Cancer Treatment Reviews, vol.26, issue.3, pp.151-68, 2000. ,
DOI : 10.1053/ctrv.1999.0161
Survival of metastatic breast carcinoma patients over a 20-year period, Cancer, vol.26, issue.8, pp.1742-50, 2005. ,
DOI : 10.1002/14651858.CD003366
Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT), Annals of Oncology, vol.21, issue.5, pp.942-950, 2010. ,
DOI : 10.1093/annonc/mdp407
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol Off J Eur Soc Med Oncol ESMO. sept, vol.22, issue.6, pp.12-24, 2011. ,
Trastuzumab après progression chez les patientes HER2+ ayant un cancer du sein avancé : résultats de l'étude GBG-26/BIG 03-05, Lett Cancérologue. juin, vol.XVIII, issue.6, 2009. ,
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer, Nature Medicine, vol.10, issue.2, pp.145-152, 2004. ,
DOI : 10.1038/nm988
de financement de la sécurité sociale pour, 1199. ,
Santé -Dépenses de santé [Internet], Disponible sur, 2014. ,
Resource use and costs associated with different states of breast cancer, International Journal of Technology Assessment in Health Care, vol.86, issue.02, pp.223-254, 2000. ,
DOI : 10.1007/978-1-4757-6822-0
Health care costs for treatment of disseminated breast cancer, European Journal of Cancer, vol.45, issue.11, pp.1987-1991, 2009. ,
DOI : 10.1016/j.ejca.2009.03.023
Treatment of Metastatic Breast Cancer, American Journal of Clinical Oncology, vol.32, issue.4, pp.369-74, 2009. ,
DOI : 10.1097/COC.0b013e31818c08d3
Treatment patterns, clinical outcomes and health care costs associated with her2-positive breast cancer with central nervous system metastases: a French multicentre observational study, BMC Health Services Research, vol.108, issue.2, p.456, 2013. ,
DOI : 10.1007/s10549-007-9601-0
Plateforme de donnée de vie réelle ESME. Constitution d'une liste de sélection exhaustive multi-source.Revue d'épidémiologie et de, pp.117-136, 2016. ,
Burden of breast cancer with brain metastasis: a French national hospital database analysis, Journal of Medical Economics, vol.15, issue.3, pp.493-499 ,
DOI : 10.3111/13696998.2012.662924
Cost-Effectiveness Analysis of Trastuzumab (Herceptin) in HER2-Overexpressed Metastatic Breast Cancer, American Journal of Clinical Oncology, vol.32, issue.5, pp.492-498, 2009. ,
DOI : 10.1097/COC.0b013e3181931277
Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis, Breast Cancer Research and Treatment, vol.27, issue.12, pp.297-305, 2008. ,
DOI : 10.1007/s10549-007-9601-0